Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials

BACKGROUND: Proton pump inhibitors (PPIs) may interfere with the metabolic activation of clopidogrel via inhibition of cytochrome P450 2C19, but the clinical implications remain unclear. METHODS AND RESULTS: The impact of PPI use on the 1‐year primary end point (ischemic stroke, myocardial infarctio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunn, Steven P., Steinhubl, Steven R., Bauer, Deborah, Charnigo, Richard J., Berger, Peter B., Topol, Eric J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603228/
https://www.ncbi.nlm.nih.gov/pubmed/23525436
http://dx.doi.org/10.1161/JAHA.112.004564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603228/
https://www.ncbi.nlm.nih.gov/pubmed/23525436
http://dx.doi.org/10.1161/JAHA.112.004564

Ejemplares similares